Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec discusses the therapeutic areas Gilead’s pipeline will focus on in the future, the importance of licensing/acquisition deals and pursuing additional indications for some of the firm’s currently marketed products.
You may also be interested in...
Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.
Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.
Parion Lands Monster Deal With Gilead For Cystic Fibrosis Candidate
With another CF candidate in Phase III, Gilead looks to build a respiratory disease franchise, R&D chief tells “The Pink Sheet” DAILY.